SLS insider buying and SEC filings, explained
SELLAS Life Sciences Group, Inc. · CIK 1390478
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$101K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Nov 19, 2025 | Purchase (code P) | Katherine Bach Kalin (Director) bought 63,400 shares at about $1.59 ($101K), reported as a purchase (code P). Holdings up 155% to 104,400 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 21, 2025 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SLS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.